Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: SMMT

Summit Therapeutics Inc.

Healthcare | Biotechnology

No licensed closing price on file for SMMT. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Summit Therapeutics Inc. (NASDAQ: SMMT) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 01:50 UTC.

What Summit Therapeutics Inc. does

Summit Therapeutics is a biopharmaceutical company developing medicines intended to improve quality of life and address unmet medical needs, with a focus on oncology. The company's lead candidate is ivonescimab, a bispecific antibody combining immunotherapy and anti-angiogenesis effects in a single molecule, which the company licensed from Akeso with rights to develop and commercialize in the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa.

Summarized from Summit Therapeutics Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
Return on equity-62.20%
Debt/equity0.16

Revenue, margins & earnings

FY2021: net loss $89M on revenue $2M$2MFY2021FY2022: net loss $79M on revenue $705,000$705,000FY2022
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-14
  • 2026-10-14Chief Accounting OfficerAward100,000—
  • 2026-06-12Co-Chief Executive OfficerPurchase3,810,000$49.99M
  • 2026-06-12Co-Chief Executive OfficerPurchase3,810,000$49.99M
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Summit Therapeutics Inc. do?

Summit Therapeutics is a biopharmaceutical company developing medicines intended to improve quality of life and address unmet medical needs, with a focus on oncology.

When did SMMT last file with the SEC?

Summit Therapeutics Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-12. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 01:50 UTC. This page is also available as JSON at /api/data?ticker=SMMT and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for SMMT and 5,000+ tickers.

Create a free account — keep SMMT
For your agent
GET /api/data?ticker=SMMT

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt